Day 1 - Exosomes Europe
- Steffen Goletz, PhD - Full Professor, Head of Biotherapeutic Glycoengineering and Immunology - Institute for Biotechnology & Biomedicine, Danish Technical University
- Bernd Giebel - Professor for Translational Extracellular Vesicle Research at University Hospital Essen and Co-Founder & CSO, Exosla Therapeutics
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
JAMA Therapeutics (JAMA Tx) is a preclinical-stage biotechnology company developing engineered extracellular vesicle platforms and genetic medicines for inherited cardiovascular and genetically defined neurodegenerative disorders. Its proprietary deVINCI and NEO platforms engineer extracellular vesicles for the transient, DNA-free intracellular delivery of genetic medicine. At Exosome Europe, JAMA Tx will present data on enhanced cargo loading and intracellular delivery, heart-selective delivery in vivo, and nanobody-directed targeting of engineered extracellular vesicles to the heart and brain. The company is building an internal therapeutic pipeline while advancing its scalable delivery platform technologies for co-development and strategic partnerships.
- Nazma Ilahibaks - CEO & Co-Founder, JAMA Therapeutics
- Robert Mamoun - CEO, Ciloa
- Lior Shaltiel - CEO, NurExone Biologic
- Rajeev Tawar - Associate Director, Vector and Analytical Development, Independent
This presentation will showcase technologies for engineering and screening targeted extracellular vesicles, focusing on their application to tissue-specific delivery, candidate selection, and the biological barriers that must be overcome for successful clinical translation.
- Alena Ivanova - Senior Scientist, AstraZeneca
- Shiran Shapira - CTO/CSO, Nano24